Latest From BlueRock Therapeutics
Century Therapeutics brings in $250m for its cell therapy programs in a series A round, while immunotherapy specialist BioNTech sets a record for series B, raising $350m. Another five firms brought in rounds of $100m or greater...
Bayer will acquire the 40.8% of BlueRock that it doesn't already own as the firm's largest investor via a $225m series A round in 2016. A clinical trial for BlueRock's Parkinson's disease candidate is expected to begin later this year.
Bayer’s VC LEAPS program invests in a second new biotech this month through its participation in the series A funding round for new immuno-oncology biotech Pyxis Oncology.
- Gene Therapy, Cell Therapy
- Therapeutic Areas
- Immune Disorders
- Neurology, Nervous System
- North America
- Company Type
- Parent & Subsidiaries
- BlueRock Therapeutics
- Senior Management
Emile Nuwaysir, PhD, Pres. & CEO
Shane Kovacs, CBO & CFO
Joachim Fruebis, PhD, Chief Dev. Officer
- Contact Info
Cambridge, MA 02142
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.